

Docket No. 220037US0PCT

IN RE APPLICATION OF: Lorena MUGGETTI, et al.

SERIAL NO: NEW U.S. PCT APPLICATION based on PCT/EP00/07679

FILED: HEREWITH

FOR: FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE WITH IMPROVED PHARMACOLOGICAL PROPERTIES

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an amendment in the above-identified application.

- ☒ No additional fee is required
- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
- ☒ Additional documents filed herewith: PCT Transmittal Letter/ PCT/IB/304/ Information Disclosure Statement
Form PTO-1449/ Check for \$1,130.00/ International Search Report/ Declaration
PCT/IB/308/ Request for Priority/ Cited References (5)/ International Preliminary
Examination Report

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	24	MINUS	24	0	× \$18 =	\$0.00
INDEPENDENT	5	MINUS	5	0	× \$84 =	\$0.00
		<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			+ \$280 =	\$0.00
		TOTAL OF ABOVE CALCULATIONS				\$0.00
		<input type="checkbox"/> Reduction by 50% for filing by Small Entity				\$0.00
		<input type="checkbox"/> Recordation of Assignment			+ \$40 =	\$0.00
		TOTAL				\$0.00

☐ A check in the amount of _____ is attached.

- ☒ Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- ☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Registration No. 24,618

Surinder Sachar
Registration No. 34,423



22850

Customer Number 22850
Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)

220037US-0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :

LORENA MUGGETTI ET AL. :

SERIAL NO: NEW U.S. PCT APPLN. : ATTN: APPLICATION BRANCH
(Based on PCT/EP00/07679)

FILED: HEREWITH :

FOR: FORMULATIONS FOR PARENTERAL
USE OF ESTRAMUSTINE PHOSPHATE
WITH IMPROVED PHARMACOLOGICAL
PROPERTIES

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows.

3. (Amended) A formulation according to claim 1 which is in single infusion dosage form comprising at least 1300 mg, of the estramustine phosphate.

4. (Amended) A formulation according to claim 1 which is in single infusion dosage form comprising at least 950 mg/m², of the estramustine phosphate.

5. (Amended) A formulation according to claim 1 wherein the sulfoalkyl ether cyclodextrin is a straight or branched C₁-C₆ sulfoalkyl ether cyclodextrin.

10070430-031002